Imatinib is a tyrosine kinase-specific inhibitor widely used for the treatment of chronic myeloid leukemia (CML). Studies reported the occurrence of additional cytogenetic abnormalities in the Philadelphia chromosome (Ph)-negative cell population emerging after treatment-induced suppression of the Ph-positive clone. These abnormalities were described in a relatively high proportion of patients treated with imatinib compared with the anecdotal reports of similar cases in patients treated with other drugs. However, the origin of these abnormalities as well as their biological and clinical significance are unknown.
Abruzzese, E., Gozzetti, A., Galimberti, S., Trawinska, M., Caravita, T., Siniscalchi, A., et al. (2007). Characterization of Ph-negative abnormal clones emerging during imatinib therapy. CANCER, 109(12), 2466-2472 [10.1002/cncr.22699].
Characterization of Ph-negative abnormal clones emerging during imatinib therapy
MAURIELLO, ALESSANDRO;DE FABRITIIS, PAOLO
2007-06-15
Abstract
Imatinib is a tyrosine kinase-specific inhibitor widely used for the treatment of chronic myeloid leukemia (CML). Studies reported the occurrence of additional cytogenetic abnormalities in the Philadelphia chromosome (Ph)-negative cell population emerging after treatment-induced suppression of the Ph-positive clone. These abnormalities were described in a relatively high proportion of patients treated with imatinib compared with the anecdotal reports of similar cases in patients treated with other drugs. However, the origin of these abnormalities as well as their biological and clinical significance are unknown.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
